These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21916635)

  • 21. The licensing of German drug patents confiscated during World War I: federal and private efforts to maintain control, promote production, and protect public health.
    Cooper D
    Pharm Hist; 2012; 54(1):3-32. PubMed ID: 24620480
    [No Abstract]   [Full Text] [Related]  

  • 22. Supreme Court rules in favor of 'pay-for-delay' settlements.
    Sklan A
    Pharm Pat Anal; 2013 Sep; 2(5):582-3. PubMed ID: 24386654
    [No Abstract]   [Full Text] [Related]  

  • 23. Not everyone is perfct: about off-patent drugs.
    Ann Oncol; 2001 Jun; 12(6):728. PubMed ID: 11484945
    [No Abstract]   [Full Text] [Related]  

  • 24. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 25. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 26. An economic assessment of patent settlements in the pharmaceutical industry.
    Dickey B; Orszag J; Tyson L
    Ann Health Law; 2010; 19(2):367-400, 2 p preceding i. PubMed ID: 21443148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patents: a threat to innovation?
    Manocaran M
    Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract]   [Full Text] [Related]  

  • 28. Life, death, and monopoly rights in a democratic society.
    Smith SJ
    Am J Bioeth; 2002; 2(3):43-4. PubMed ID: 12230856
    [No Abstract]   [Full Text] [Related]  

  • 29. Public positions on antitrust changes.
    West D; Costello M; Boyle K
    Adm Radiol J; 1996 Jun; 15(6):14-6, 20. PubMed ID: 10159366
    [No Abstract]   [Full Text] [Related]  

  • 30. Reach-through claims for drug target patents: Rx for pharmaceutical policy.
    Bohrer RA
    Nat Biotechnol; 2008 Jan; 26(1):55-6. PubMed ID: 18183015
    [No Abstract]   [Full Text] [Related]  

  • 31. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 32. Federal Trade Commission v. Actavis, Inc. and reverse-payment or pay-for-delay settlements.
    Sherkow JS
    Nat Biotechnol; 2013 Apr; 31(4):316-7. PubMed ID: 23563426
    [No Abstract]   [Full Text] [Related]  

  • 33. Insights for hospitals: the 1994 health care antitrust enforcement policy statements.
    Marx D; Busey RC
    J Health Hosp Law; 1995; 28(3):143-50. PubMed ID: 10155907
    [No Abstract]   [Full Text] [Related]  

  • 34. The Federal Trade Commission and physician practice.
    Graham J
    J Med Pract Manage; 2005; 20(5):259-62. PubMed ID: 15921139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitrust enforcement in pharmaceutical industry mergers.
    Balto DA; Mongoven JF
    Food Drug Law J; 1999; 54(3):255-78. PubMed ID: 11797700
    [No Abstract]   [Full Text] [Related]  

  • 36. New antitrust guidelines give providers a partial victory.
    Burda D
    Mod Healthc; 1993 Sep; 23(38):3. PubMed ID: 10128216
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceuticals and Medical Devices: Business Practices.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-38. PubMed ID: 29361660
    [No Abstract]   [Full Text] [Related]  

  • 38. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
    Whitener MD
    Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
    [No Abstract]   [Full Text] [Related]  

  • 39. Medical staff privileges and the antitrust laws: a view from the Federal Trade Commission.
    Horoschak MJ
    Med Staff Couns; 1992; 6(2):17-24. PubMed ID: 10116790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitrust--pre-merger compliance.
    Brock TH
    Health Syst Rev; 1993; 26(6):36-8. PubMed ID: 10130173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.